This article was originally published on 14 March 2008 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.
A pipeline at an inflection point
VacZine Analytics' March 2008 review of the global vaccine pipeline identified an unprecedented level of late-stage clinical activity across multiple therapeutic areas. The research suggested that by 2015, the total number of licensed vaccine products globally could approximately double from its 2007 baseline, driven by a combination of new indications in established areas (pneumococcal, meningococcal, HPV), entirely new vaccine targets (C. difficile, RSV, therapeutic cancer vaccines), and geographic expansion of existing products into previously underserved markets.
VacZine Analytics' projection for the approximate doubling in the number of licensed vaccine products by 2015, from its 2007 baseline
Key drivers of the expansion
Several converging factors were driving this exceptional pipeline activity: the commercial success of recent blockbuster launches (Gardasil, Prevnar, RotaTeq) had demonstrated the revenue potential of vaccines, attracting increased R&D investment; regulatory pathways for conjugate and recombinant vaccines had become better understood; and new modalities including virosomes, virus-like particles (VLPs), and novel adjuvant systems were producing candidates that had previously failed with conventional approaches.
"The vaccine pipeline of 2008 is more diverse, more commercially promising, and more scientifically sophisticated than at any point in the industry's history - and the pipeline of 2015 will reflect that investment."